Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Complex effects of VLA-4 antibody on autoimmune disease
  • Vitamin D receptor deficiency sends fur flying
  • Targeting thyroid hormone receptor isoforms
  • Version history
  • Article usage
  • Citations to this article

Advertisement

In this issue Free access | 10.1172/JCI119924

In This Issue

John Ashkenas, Science Editor

Find articles by Ashkenas, J. in: PubMed | Google Scholar

Published April 15, 2001 - More info

Published in Volume 107, Issue 8 on April 15, 2001
J Clin Invest. 2001;107(8):927–927. https://doi.org/10.1172/JCI119924.
© 2001 The American Society for Clinical Investigation
Published April 15, 2001 - Version history
View PDF
Complex effects of VLA-4 antibody on autoimmune disease

(See article on pages 995– 1006.)

The course of multiple sclerosis (MS) often involves not a steady progressive decline of motor control, but a sequence of declines, punctuated by intervals of partial recovery. Work in a mouse model that mimics this "relapsing remitting" form of MS shows that the T cells involved at the onset of autoimmune disease differ from those that drive the later relapses. Thus, the epitopes recognized on the proteolipid protein (PLP) immunogen, which is used to initiate disease in this model, are different for the T cells that initially breach the blood-brain barrier and for the subsequent rounds of T-cell expansion seen later in the disease. Theien and colleagues have now identified another difference between these T-cell populations, related to their adhesive interactions. The integrin VLA-4 is implicated in adhesion of T cells to the endothelium, and several reports suggest that blocking antibody can ameliorate MS or other autoimmune disorders. Theien et al. find, however, that this treatment is only beneficial if begun early, before the onset of clinical disease. If applied later, this same antibody increases both the severity of disease and the rate of remission. The authors argue that T cells in an animal already primed to respond to PLP can reach their target in the CNS by interactions independent of VLA-4, and they suggest that the antibody exacerbates the response of these cells by mimicking the effect of normal costimulatory signals.

Vitamin D receptor deficiency sends fur flying

(See article on pages 961–966.)

Hair follicles consist largely of one epithelial cell type, the keratinocyte, and one mesenchymal cell type, the dermal papillar cell. Interactions between these two classes of cell are crucial for maintenance of the follicle and continued growth of hair. Sakai and coworkers have previously observed that mice lacking the vitamin D receptor (VDR), a nuclear receptor expressed in both of these cell populations, lose their hair early in postnatal life. Here, they test several models to explain this finding. Noting that the absence of feedback regulation ordinarily causes vitamin D levels to surge to potentially toxic levels in VDR–deficient animals, Sakai et al. used a controlled diet and a UV-free environment to generate mice of both VDR+/+ and VDR–/– genotypes that completely lack this vitamin. Under these conditions, adult VDR–/– mice are still hairless, and VDR+/+ mice still have normal coats, arguing that the absence of the receptor, rather than the presence of toxic quantities of vitamin D or the absence of the vitamin D–dependent signals, must account for the failure of the follicle to maintain hair growth into adult life. To determine whether this unexpected VDR function occurs in keratinocytes or papillar cells, the authors then used the VDR–/– and VDR–/– mice as a source of purified mesenchymal and epithelial cells and transplanted these cells into recipient mouse skin. Only the keratinocyte population, they show, requires VDR to sustain the normal hair cycle. How the VDR might support keratinocyte and follicle function even in the absence of its known ligands remains unclear.

Targeting thyroid hormone receptor isoforms

(See article on pages 1017– 1023.)

Specialized neurons in the paraventricular nucleus of the hypothalamus produce thyrotropin-releasing hormone (TRH), a key regulator of thyroid hormone levels, and hence of metabolic rate. In a previous JCI paper, Abel and colleagues developed a mouse specifically lacking one of the alternatively spliced isoforms of the thyroid hormone receptor TR-β2, and they showed that TR-β1 and the other receptor isoforms are expressed normally in these mutant animals. TR-β2 is restricted in its expression but is found prominently in TRH neurons. Following up on hints that the different isoforms carry out distinct functions in thyroid hormone regulation, these same authors now show that TR-β2 is required for the silencing of TRH expression. TRH is therefore highly expressed in the mutant mice under basal conditions, but it does not respond to either hypothyroid conditions or treatment with exogenous thyroid hormones. As predicted, the animals are capable of regulating TRH in response to leptin and other stimuli, confirming that the defect is specific to the feedback system that regulates thyroid hormones.

Version history
  • Version 1 (April 15, 2001): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Complex effects of VLA-4 antibody on autoimmune disease
  • Vitamin D receptor deficiency sends fur flying
  • Targeting thyroid hormone receptor isoforms
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts